menu
    • menu

    Company profile for Daiichi Sankyo

    Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients, & custom-made solutions to our customers.

    Virtual Booth

    Contact Supplier

    Inke S.A: APIs manufacturing plant.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2025-04-21

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2025-04-14

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Daiichi Sankyo is a global pharmaceutical company with corporate origins in Japan. We provide innovative products and services in more than 20 countries around the world. With more than 100 years of scientific expertise, our company draws upon a rich legacy of innovation and a robust pipeline of promising new medicines to help patients. Through the outstanding knowledge and commitment of our 15,000 employees worldwide, we crea...
    Daiichi Sankyo is a global pharmaceutical company with corporate origins in Japan. We provide innovative products and services in more than 20 countries around the world. With more than 100 years of scientific expertise, our company draws upon a rich legacy of innovation and a robust pipeline of promising new medicines to help patients. Through the outstanding knowledge and commitment of our 15,000 employees worldwide, we create innovative new and generic medicines, and new methods of drug discovery and delivery. We share a passion for innovation, as well as compassion for the patients around the world who are in need of our medicines.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Daiichi Sankyojapan Flag
    Country
    Country
    Japan
    Address
    Address
    3-5-1, Nihonbashi-honcho, Chuo-ku, Tokyo 103-8426
    Telephone
    Telephone
    +81-3-6225-1111
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.daiichisankyo.com/
    Linkedin
    Linkedin
    https://in.linkedin.com/company/daiichi-sankyo
    youtube
    YouTube
    Twitter
    Twitter
    https://x.com/daiichisankyo?lang=en

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    CPhI North America

    Not Confirmed

    envelop Contact Supplier

    CPhI North America

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    INTERVIEW #SpeakPharma

    [Sponsored by another company]
    “Our unmatched efficiency and track record of faster DMF filings give our customers a critical competitive advantage”

    “Our unmatched efficiency and track record of faster DMF filings give our customers a critical competitive advantage”

    This week, SpeakPharma interviews Pete Werth III, the new president of ChemWerth, a company that has been at the forefront of the generic pharmaceutical industry for over four decades. He shares his vision for ChemWerth, which includes his commitment to strengthening global manufacturing relationships, and enhancing supply chain resilience. Additionally, he highlights the key aspects of a successful drug master file (DMF). HIGHLIGHTS// Pete Werth III, the new president of ChemWerth/ vision for ChemWerth/ commitment to strengthening global manufacturing relationships/ key aspects of a successful drug master file Your father, Peter J. Werth, is recognized as one of the founders of the generic pharmaceutical industry, having built ChemWerth from the ground up over four decades ago. How do you view his legacy? As you take the helm, what key lessons or principles from his leadership do you intend to carry forward? My father, Peter J. Werth, is a true pioneer in the generic pharmaceutical industry. Over his 42‐year tenure, he not only built ChemWerth from a humble garage startup into a global leader in generic API development but also established standards that many in our industry now take for granted. Under his leadership, we filed our very first DMF in 1987 and have since achieved more than 500 DMF filings. With an average review cycle of just 0.79, we have been far outperforming the industry average of 2.5 cycles. His focus on quality, regulatory excellence, and a relentless commitment to customers’ success set the foundation for our reputation as a trusted supplier of over 500 APIs sourced from more than 30 cGMP-certified facilities worldwide. Equally inspiring is his dedication to nurture long-term, mutually beneficial relationships with manufacturing partners across the US, Europe, India, and China, as well as his passion for giving back to the community through philanthropic initiatives. As I take the helm, I intend to build on his guiding principles — sustaining our high standards of quality and compliance while pursuing innovation in regulatory strategy, diversifying our supply chain, and embracing new technologies and approaches to remain competitive in an evolving market. I will also strive to continue his legacy of mentorship, ensuring that our company culture remains rooted in integrity and diligence, with an unyielding focus on making safe, affordable medicines available worldwide. HIGHLIGHTS// trusted supplier of over 500 APIs/ 30 cGMP-certified facilities worldwide/ embracing new technologies and approaches to remain competitive What are your top priorities as the new president of ChemWerth? How do you plan to strengthen and expand relationships with manufacturers worldwide? My immediate priorities as the new president are twofold: to enhance the value we deliver to our customers and, to deepen our relationships with our manufacturing partners worldwide. We will further diversify our supply chain and broaden our product portfolio. Our expansion plans include upgrading equipment, and hiring additional highly skilled scientists, engineers, and GMP auditors. We will also leverage our proprietary product selection and regulatory submission processes. These processes help us get the regulatory filing right the first time, and allows us to be approved 44 percent faster than the industry average. This helps our customers gain a competitive edge in the market. In essence, by strengthening operational excellence and expanding our global network, we intend to continue the company’s long-standing commitment to customer success and process innovation. We plan to reinforce our long-standing relationships with our manufacturers — especially those in strategic markets like China and India — by helping our partners meet the highest standards of regulatory compliance and current good manufacturing practice (cGMP) quality. This balanced approach of strengthening existing partnerships while pioneering new ones is key to maintaining and growing our competitive edge. HIGHLIGHTS// diversify our supply chain and broaden our product portfolio/ commitment to customer success and process innovation/ filings approved 44 percent faster than the industry average When ChemWerth last spoke to PharmaCompass, there was a mention of investing millions of dollars in expanding manufacturing partnerships in China and India. Can you elaborate on the success of these partnerships, and how have they contributed to ChemWerth’s overall growth? Our strategic, multimillion-dollar investments in manufacturing partnerships are a cornerstone of our growth strategy. Over the past few years, these joint ventures have proven their worth by diversifying our supply base and mitigating the risk of global supply chain disruptions — a lesson that became all too clear during the Covid-19 pandemic. These investments are already paying dividends. They help us support manufacturers producing steroids, hormones, veterinary products, and large-volume APIs, while also accelerating the development of small-molecule inhibitors and new generic APIs. We have ensured that our partners are equipped with the latest equipment and trained personnel to meet cGMP standards. By partnering with facilities in these markets, we now have access to state-of-the-art production capabilities that enable us to produce a wider range of APIs at competitive costs. The success of these partnerships is evident in our ability to consistently file DMFs rapidly — often on the first cycle — and deliver affordable, high-quality medicines to patients worldwide. This supports our clients’ growth trajectory and has helped us expand into new markets. This strategy has reinforced our global footprint — supporting our presence in 38 countries with over 100 products — and positioned us well to capitalize on a global generic drug market projected to grow at a compounded annual growth rate of 5.4 percent from 2022 to 2030, to reach a size of US$ 671 billion by 2030. HIGHLIGHTS// strategic multimillion-dollar investments/ support manufacturers producing steroid, hormone, veterinary products/ development of small-molecule inhibitors and new generic APIs/ ensured partners are equipped with the latest equipment and trained personnel ChemWerth has an impressive track record, and an over 40-year relationship with the US Food and Drug Administration (FDA). What are the key aspects of a successful DMF? Are there specific challenges manufacturers face in preparing DMFs, and how does ChemWerth help them overcome these hurdles? ChemWerth’s record of filing over 500 DMFs in 38 countries reflects our commitment to excellence in regulatory compliance and quality management. A successful DMF is built on comprehensive documentation that rigorously follows cGMP guidelines, robust analytical validation, and detailed tracking of every step. Every DMF we file meticulously details the entire manufacturing process — from raw material acquisition to final batch production. This comprehensive approach ensures that our submissions meet the rigorous quality, safety, and efficacy standards expected by the FDA. Our team stays continuously updated on the evolving guidelines and protocols, which allows us to file DMFs that align with current FDA practices. We recognize that many manufacturers face challenges such as complex regulatory requirements, lengthy review cycles, and the need for precise coordination between various production stages. ChemWerth helps them overcome these hurdles by offering end-to-end regulatory support, detailed internal audits, and continuous training on cGMP and FDA requirements. Our efficiency is a critical competitive advantage. By receiving approvals 44 percent faster than the industry average, we help our customers get their products to market faster, resulting in larger market share and increased profits. HIGHLIGHTS// over 500 DMFs in 38 countries/ robust analytical validation/ end-to-end regulatory support What is your vision for ChemWerth over the next few years? How do you plan to navigate the challenges and opportunities in the generic pharmaceutical industry? I plan to continue to add value for our customers, and look for innovative ways to compete in today’s generic pharmaceutical landscape. At ChemWerth, our vision for the future is rooted in both our proud legacy and our relentless drive for innovation. We will further diversify our supply chain and expand our product portfolio. We have begun leveraging our expertise to supply APIs for biosimilars and new drug applications (NDAs), while maintaining our reputation for rapid regulatory approvals. With unwavering determination, we uphold our “First to Quality. Fast to Market.” approach — delivering high-quality APIs to customers worldwide while leveraging our expertise to give them a competitive edge in their markets. HIGHLIGHTS// supply APIs for biosimilars and NDAs/ give customers a competitive edge in their markets 

    Impressions: 955

    subscribeSubscribe

    https://www.pharmacompass.com/speak-pharma/our-unmatched-efficiency-and-track-record-of-faster-dmf-filings-give-our-customers-a-critical-competitive-advantage

    Radio Compass
    12 Mar 2025
    Share info Share

    VLOG #PharmaReel

    [Sponsored by another company]

    DATA COMPILATION #PharmaFlow

    [Sponsored by another company]
    Top Pharma Companies & Drugs in 2024: Merck’s Keytruda maintains top spot as Novo’s semaglutide nips at its heels

    Top Pharma Companies & Drugs in 2024: Merck’s Keytruda maintains top spot as Novo’s semaglutide nips at its heels

    In 2024, Big Pharma players consolidated and maintained their dominance, even as innovation continued to reshape the pharmaceutical landscape. The primary change last year was the meteoric rise of glucagon-like peptide-1 (GLP-1) receptor agonists that treat diabetes and help in weight loss.Amongst drugmakers, Pfizer retained its numero uno spot with an impressive US$ 63.6 billion in prescription drug sales (up 7 percent from US$ 59.56 billion reported in 2023), despite ever-shrinking Comirnaty sales, which settled at US$ 5.35 billion in 2024 (from US$ 11.22 billion in 2023).Merck secured the second position with revenues of US$ 57.4 billion, a growth of 7 percent over 2023. This performance was predominantly fueled by Keytruda, which now accounts for more than half of Merck’s total pharmaceutical revenue. Johnson & Johnson came a close third with US$ 57 billion in prescription drug sales (up from US$ 54.76 billion in 2023).AbbVie held the fourth position with US$ 56.33 billion in sales, achieving 3.7 percent growth despite the ongoing erosion of Humira revenue. This flagship immunology drug saw sales plummet 37.6 percent to approximately US$ 9 billion, a US$ 5.4 billion reduction compared to 2023. Humira’s loss was offset by AbbVie’s newer immunology assets, particularly Skyrizi and Rinvoq, both of which demonstrated exceptional growth trajectories. View Our Interactive Dashboard on Top Drugs in 2024 by Sales (Free Excel Available)European giants Astra, Roche, Novartis, Sanofi round out top 10 list; Novo, Lilly see astounding growthWhile the top four positions were dominated by American drugmakers, European giants dominated the lower half of the top 10 list.AstraZeneca secured the fifth spot with US$ 54.1 billion in sales, thereby posting impressive growth of 18.1 percent over 2023. Roche claimed the sixth position with US$ 50.9 billion in sales while Novartis ranked seventh — with sales of US$ 50.3 billion. Novartis' impressive 10.8 percent sales growth is attributed to its innovative medicines portfolio. Oncology therapies remained a cornerstone for both these Swiss drugmakers.Bristol Myers Squibb (BMS) secured eighth position with revenues of US$ 48.3 billion, representing 7.3 percent growth over the previous year. At US$ 45 billion, Eli Lilly posted 32 percent revenue growth last year. Its GLP-1 drug Mounjaro helped Lilly move up from the tenth in 2023 to the ninth spot last year.Sanofi landed the tenth position with US$ 42.6 billion in sales, propelled largely by the expanding indications of Dupixent. The French multinational has increasingly focused on this immunology blockbuster, while also garnering more sales from its vaccine and rare disease portfolios.Novo Nordisk merits a mention as it posted an incredible 26 percent year-on-year growth. It retained its eleventh spot with US$ 40.25 billion in sales. Novo’s growth was driven almost exclusively by the extraordinary success of its GLP-1 receptor agonist portfolio. View Our Interactive Dashboard on Top Drugs in 2024 by Sales (Free Excel Available)       Merck’s Keytruda retains throne with US$ 29.5 bn in sales, as Novo’s semaglutide nips at its heelsMoving on to drugs, Merck’s Keytruda (pembrolizumab) solidified its position as the world’s top-selling pharmaceutical product with sales exceeding US$ 29.5 billion and year-on-year growth of 17.88 percent (US$ 4.5 billion). This remarkable performance was driven by steady sales growth across more than 40 indications in the US. In 2024 alone, Keytruda secured four new approvals from the US Food and Drug Administration (FDA).However, Novo Nordisk’s semaglutide sales (Ozempic, Wegovy and Rybelsus) gave Keytruda a run for its money. Across the three blockbuster drugs, semaglutide earned the Danish drugmaker around US$ 28 billion — i.e. a year-on-year increase of 38 percent.Novo’s Ozempic (semaglutide) reached over US$ 16.7 billion in sales — a 20 percent increase from 2023. Originally approved in 2017 to improve glycemic control, Ozempic bagged additional approvals in 2020, and in January 2025. It is now approved to reduce the risk of major cardiovascular events, as well as to reduce cardiovascular risk and to lower the likelihood of chronic kidney disease in type 2 diabetes patients.Sales of Wegovy (semaglutide), the other blockbuster GLP-1 drug from Novo, grew by a whopping 85.7 percent to over US$ 8 billion.Sanofi and Regeneron’s Dupixent (dupilumab) secured the number three spot with sales of US$ 13.6 billion, representing an impressive 17.2 percent year-on-year growth. In 2024, Dupixent received three new approvals and one label update. Notably, it became the first-ever biologic medicine approved for patients with chronic obstructive pulmonary disease (COPD). View Our Interactive Dashboard on Top Drugs in 2024 by Sales (Free Excel Available) AbbVie’s post-Humira strategy pays off as Skyrizi surges 51%; Lilly’s Mounjaro posts 124% growthGilead Sciences’ HIV treatment Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) showed robust growth of 13.27 percent, touching sales of US$ 13.42 billion in 2024 and emerging as the fourth largest selling drug. Biktarvy now commands over 50 percent of the US HIV treatment market. Unlike many other drugs on this list, Biktarvy faces no immediate patent challenges, with key protections expected to remain intact until 2033.BMS and Pfizer’s anticoagulant Eliquis (apixaban) claimed the fifth position with US$ 13.33 billion in sales, representing a 9.21 percent year-on-year increase. AbbVie’s Skyrizi (risankizumab) emerged as one of the fastest-growing assets with a 50.95 percent year-on-year increase, generating US$ 11.71 billion in 2024 sales, thereby surpassing Humira’s (adalimumab) diminished sales.This impressive performance, combined with Rinvoq’s (upadacitinib) growth, has prompted  AbbVie to raise its long-term outlook for these products. The company now expects combined Skyrizi and Rinvoq revenues to exceed US$ 31 billion by 2027, with Skyrizi alone projected to generate over US$ 20 billion.Johnson & Johnson’s Darzalex (daratumumab) claimed the seventh position with US$ 11.67 billion in sales, representing 19.77 percent growth over 2023.Lilly’s Mounjaro (tirzepatide) demonstrated dramatic growth with sales increasing 123.51 percent to US$ 11.54 billion. This performance was complemented by Zepbound (tirzepatide, for weight loss), which contributed US$ 4.9 billion to Lilly’s revenue. By the end of 2024, Mounjaro received FDA approval for a new indication in obstructive sleep apnea (OSA), becoming the first and only prescription medicine for moderate-to-severe OSA in adults with obesity.Stelara (ustekinumab) ranked ninth, bringing J&J sales of US$ 10.36 billion, showing a modest decline of 4.91 percent from its 2023 sales.Vertex’s triple-combination therapy Trikafta (elexacaftor/tezacaftor/ivacaftor) for treating cystic fibrosis rounded out the top ten list with sales of US$ 10.2 billion, up 14 percent from the previous year. View Our Interactive Dashboard on Top Drugs in 2024 by Sales (Free Excel Available) Our viewIn 2024, transformative therapies like GLP-1 receptor agonists drove growth in the pharmaceutical industry. This year, we expect GLP-1 drugs to dethrone Keytruda from the number one spot. Along with novel immunology agents, we expect GLP-1 drugs to realign the pharmaceutical market.  
    subscribeSubscribe
    ExcelExcel Download

    Impressions: 2173

    https://www.pharmacompass.com/radio-compass-blog/top-pharma-companies-drugs-in-2024-merck-s-keytruda-maintains-top-spot-as-novo-s-semaglutide-nips-at-its-heels

    #PharmaFlow by PHARMACOMPASS
    24 Apr 2025
    Share Share

    NEWS #PharmaBuzz

    read-more
    read-more
    Enhertu drives strong efficacy in first-line breast cancer
    Enhertu drives strong efficacy in first-line breast cancer

    22 Apr 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250420186313/en/ENHERTU-Plus-Pertuzumab-Demonstrated-Highly-Statistically-Significant-and-Clinically-Meaningful-Improvement-in-Progression-Free-Survival-Versus-THP-as-First-Line-Therapy-for-Patients-with-HER2-Positive-Metastatic-Breast-Cancer

    BUSINESSWIRE
    22 Apr 2025
    Share Share
    Daiichi Sankyo honors its roots at DC cherry blossom fest
    Daiichi Sankyo honors its roots at DC cherry blossom fest

    17 Apr 2025

    // FIERCE PHARMA

    https://www.fiercepharma.com/marketing/daiichi-sankyo-celebrates-its-roots-and-blooming-future-dc-cherry-blossom-festival

    FIERCE PHARMA
    17 Apr 2025
    Share Share
    Datroway® EU approval for metastatic HR+, HER2- breast cancer.
    Datroway® EU approval for metastatic HR+, HER2- breast cancer.

    08 Apr 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250407125323/en/DATROWAY-Approved-in-the-EU-for-Patients-with-Previously-Treated-Metastatic-HR-Positive-HER2-Negative-Breast-Cancer

    BUSINESSWIRE
    08 Apr 2025
    Share Share
    Enhertu Approved in EU as First HER2 Therapy for HR+ Breast Cancer
    Enhertu Approved in EU as First HER2 Therapy for HR+ Breast Cancer

    05 Apr 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250403813366/en/ENHERTU-Approved-in-the-EU-as-First-HER2-Directed-Therapy-for-Patients-with-HR-Positive-HER2-Low-or-HER2-Ultralow-Metastatic-Breast-Cancer-Following-at-Least-One-Endocrine-Therapy

    BUSINESSWIRE
    05 Apr 2025
    Share Share
    ENHERTU® Phase 3 Trial Begins for HER2+ Advanced Gastric Cancer
    ENHERTU® Phase 3 Trial Begins for HER2+ Advanced Gastric Cancer

    01 Apr 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250328673005/en/DESTINY-Gastric05-Phase-3-Trial-of-ENHERTU-Initiated-in-Patients-with-Previously-Untreated-HER2-Positive-Advanced-Gastric-Cancer

    BUSINESSWIRE
    01 Apr 2025
    Share Share
    Daiichi taps Nosis to deliver RNA therapies beyond the liver
    Daiichi taps Nosis to deliver RNA therapies beyond the liver

    12 Mar 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250311961776/en/Nosis-Biosciences-Announces-Research-Collaboration-and-Option-Agreement-with-Daiichi-Sankyo-to-Develop-Cell-Targeted-RNA-Medicines

    BUSINESSWIRE
    12 Mar 2025
    Share Share

    Drugs in Development

    read-more
    read-more
    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    DATROWAY Approved in EU for HER2- Breast Cancer After Prior Treatment

    Details:

    Datroway (datopotamab deruxtecan) is a specifically engineered TROP2 directed DXd ADC, approved for adults with unresectable or metastatic HR positive, HER2 negative breast cancer.


    Lead Product(s): Datopotamab Deruxtecan

    Therapeutic Area: Oncology Brand Name: Datroway

    Study Phase: Approved FDFProduct Type: Antibody-drug Conjugate

    Sponsor: AstraZeneca

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable April 08, 2025

    blank

    01

    Daiichi Sankyo

    Japan
    arrow
    AACR Annual meeting
    Not Confirmed

    Daiichi Sankyo

    Japan
    arrow
    AACR Annual meeting
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Datopotamab Deruxtecan

    Therapeutic Area : Oncology

    Highest Development Status : Approved FDF

    Partner/Sponsor/Collaborator : AstraZeneca

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    DATROWAY Approved in EU for HER2- Breast Cancer After Prior Treatment

    Details : Datroway (datopotamab deruxtecan) is a specifically engineered TROP2 directed DXd ADC, approved for adults with unresectable or metastatic HR positive, HER2 negative breast cancer.

    Product Name : Datroway

    Product Type : Antibody-drug Conjugate

    Upfront Cash : Inapplicable

    April 08, 2025

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Enhertu Initiated in Patients with Previously Untreated HER2 Positive Gastric Cancer

    Details:

    Enhertu (trastuzumab deruxtecan) in combination with fluoropyrimidine chemotherapy, pembrolizumab is being studied for unresectable, locally advanced or metastatic HER2 positive gastric or GEJ cancer.


    Lead Product(s): Trastuzumab Deruxtecan,Cisplatin,Pembrolizumab

    Therapeutic Area: Oncology Brand Name: Enhertu

    Study Phase: Phase IIIProduct Type: Antibody-drug Conjugate

    Sponsor: Merck & Co

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable March 31, 2025

    blank

    02

    Daiichi Sankyo

    Japan
    arrow
    AACR Annual meeting
    Not Confirmed

    Daiichi Sankyo

    Japan
    arrow
    AACR Annual meeting
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Trastuzumab Deruxtecan,Cisplatin,Pembrolizumab

    Therapeutic Area : Oncology

    Highest Development Status : Phase III

    Partner/Sponsor/Collaborator : Merck & Co

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Enhertu Initiated in Patients with Previously Untreated HER2 Positive Gastric Cancer

    Details : Enhertu (trastuzumab deruxtecan) in combination with fluoropyrimidine chemotherapy, pembrolizumab is being studied for unresectable, locally advanced or metastatic HER2 positive gastric or GEJ cancer.

    Product Name : Enhertu

    Product Type : Antibody-drug Conjugate

    Upfront Cash : Inapplicable

    March 31, 2025

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    CHMP Recommends Datopotamab Deruxtecan for HR+/HER2- Breast Cancer

    Details:

    Datroway (datopotamab deruxtecan) is a specifically engineered TROP2 directed DXd ADC, approved for adults with unresectable or metastatic HR positive, HER2 negative breast cancer.


    Lead Product(s): Datopotamab Deruxtecan

    Therapeutic Area: Oncology Brand Name: Datroway

    Study Phase: Approved FDFProduct Type: Antibody-drug Conjugate

    Sponsor: AstraZeneca

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable January 31, 2025

    blank

    03

    Daiichi Sankyo

    Japan
    arrow
    AACR Annual meeting
    Not Confirmed

    Daiichi Sankyo

    Japan
    arrow
    AACR Annual meeting
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Datopotamab Deruxtecan

    Therapeutic Area : Oncology

    Highest Development Status : Approved FDF

    Partner/Sponsor/Collaborator : AstraZeneca

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    CHMP Recommends Datopotamab Deruxtecan for HR+/HER2- Breast Cancer

    Details : Datroway (datopotamab deruxtecan) is a specifically engineered TROP2 directed DXd ADC, approved for adults with unresectable or metastatic HR positive, HER2 negative breast cancer.

    Product Name : Datroway

    Product Type : Antibody-drug Conjugate

    Upfront Cash : Inapplicable

    January 31, 2025

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Datroway Phase 3 Begins for NSCLC Patients at High Relapse Risk

    Details:

    Datroway (datopotamab deruxtecan), an TROP2 ADC, plus rilvegostomig, A PD-1/TIGIT bispecific antibody, is being investigated in patients with stage 1 adenocarcinoma non-small cell lung cancer.


    Lead Product(s): Datopotamab Deruxtecan,Rilvegostomig

    Therapeutic Area: Oncology Brand Name: Datroway

    Study Phase: Phase IIIProduct Type: Antibody-drug Conjugate

    Sponsor: AstraZeneca

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable January 30, 2025

    blank

    04

    Daiichi Sankyo

    Japan
    arrow
    AACR Annual meeting
    Not Confirmed

    Daiichi Sankyo

    Japan
    arrow
    AACR Annual meeting
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Datopotamab Deruxtecan,Rilvegostomig

    Therapeutic Area : Oncology

    Highest Development Status : Phase III

    Partner/Sponsor/Collaborator : AstraZeneca

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Datroway Phase 3 Begins for NSCLC Patients at High Relapse Risk

    Details : Datroway (datopotamab deruxtecan), an TROP2 ADC, plus rilvegostomig, A PD-1/TIGIT bispecific antibody, is being investigated in patients with stage 1 adenocarcinoma non-small cell lung cancer.

    Product Name : Datroway

    Product Type : Antibody-drug Conjugate

    Upfront Cash : Inapplicable

    January 30, 2025

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    DATROWAY® Approved in U.S. for Metastatic HR+ HER2- Breast Cancer

    Details:

    Datroway (datopotamab deruxtecan) is a specifically engineered TROP2 directed DXd ADC, approved in the U.S. for adults with unresectable or metastatic HR positive, HER2 negative breast cancer.


    Lead Product(s): Datopotamab Deruxtecan

    Therapeutic Area: Oncology Brand Name: Datroway

    Study Phase: Approved FDFProduct Type: Antibody-drug Conjugate

    Sponsor: AstraZeneca

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable January 17, 2025

    blank

    05

    Daiichi Sankyo

    Japan
    arrow
    AACR Annual meeting
    Not Confirmed

    Daiichi Sankyo

    Japan
    arrow
    AACR Annual meeting
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Datopotamab Deruxtecan

    Therapeutic Area : Oncology

    Highest Development Status : Approved FDF

    Partner/Sponsor/Collaborator : AstraZeneca

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    DATROWAY® Approved in U.S. for Metastatic HR+ HER2- Breast Cancer

    Details : Datroway (datopotamab deruxtecan) is a specifically engineered TROP2 directed DXd ADC, approved in the U.S. for adults with unresectable or metastatic HR positive, HER2 negative breast cancer.

    Product Name : Datroway

    Product Type : Antibody-drug Conjugate

    Upfront Cash : Inapplicable

    January 17, 2025

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Datopotamab Deruxtecan Gets Priority Review for EGFR-Mutated NSCLC

    Details:

    Dato-DXd (datopotamab deruxtecan) is a DNA topoisomerase I inhibitor candidate, which is being developed in patients with EGFR-mutated non-small cell lung cancer.


    Lead Product(s): Datopotamab Deruxtecan

    Therapeutic Area: Oncology Brand Name: Dato-DXd

    Study Phase: Phase IIIProduct Type: Antibody-drug Conjugate

    Sponsor: Inapplicable

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable January 13, 2025

    blank

    06

    Daiichi Sankyo

    Japan
    arrow
    AACR Annual meeting
    Not Confirmed

    Daiichi Sankyo

    Japan
    arrow
    AACR Annual meeting
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Datopotamab Deruxtecan

    Therapeutic Area : Oncology

    Highest Development Status : Phase III

    Partner/Sponsor/Collaborator : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Datopotamab Deruxtecan Gets Priority Review for EGFR-Mutated NSCLC

    Details : Dato-DXd (datopotamab deruxtecan) is a DNA topoisomerase I inhibitor candidate, which is being developed in patients with EGFR-mutated non-small cell lung cancer.

    Product Name : Dato-DXd

    Product Type : Antibody-drug Conjugate

    Upfront Cash : Inapplicable

    January 13, 2025

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    QuANTUM-Wild Phase 3 Trial of VANFLYTA® Begins in FLT3-ITD Negative AML

    Details:

    VANFLYTA® (quizartinib) is an oral, highly potent, type II FLT3 inhibitor that selectively targets FLT3-ITD mutations and has been specifically developed for patients with FLT3-ITD positive AML.


    Lead Product(s): Quizartinib,Cytarabine,Daunorubicin

    Therapeutic Area: Oncology Brand Name: Vanflyta

    Study Phase: Approved FDFProduct Type: Other Small Molecule

    Sponsor: Inapplicable

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable December 10, 2024

    blank

    07

    Daiichi Sankyo

    Japan
    arrow
    AACR Annual meeting
    Not Confirmed

    Daiichi Sankyo

    Japan
    arrow
    AACR Annual meeting
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Quizartinib,Cytarabine,Daunorubicin

    Therapeutic Area : Oncology

    Highest Development Status : Approved FDF

    Partner/Sponsor/Collaborator : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    QuANTUM-Wild Phase 3 Trial of VANFLYTA® Begins in FLT3-ITD Negative AML

    Details : VANFLYTA® (quizartinib) is an oral, highly potent, type II FLT3 inhibitor that selectively targets FLT3-ITD mutations and has been specifically developed for patients with FLT3-ITD positive AML.

    Product Name : Vanflyta

    Product Type : Other Small Molecule

    Upfront Cash : Inapplicable

    December 10, 2024

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Datopotamab Deruxtecan Gets Breakthrough Therapy Designation for EGFR-Mutated NSCLC

    Details:

    Dato-DXd (datopotamab deruxtecan) is a DNA topoisomerase I inhibitor candidate, which is being developed in patients with EGFR-mutated non-small cell lung cancer.


    Lead Product(s): Datopotamab Deruxtecan

    Therapeutic Area: Oncology Brand Name: Dato-DXd

    Study Phase: Phase IIIProduct Type: Antibody-drug Conjugate

    Sponsor: AstraZeneca

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable December 09, 2024

    blank

    08

    Daiichi Sankyo

    Japan
    arrow
    AACR Annual meeting
    Not Confirmed

    Daiichi Sankyo

    Japan
    arrow
    AACR Annual meeting
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Datopotamab Deruxtecan

    Therapeutic Area : Oncology

    Highest Development Status : Phase III

    Partner/Sponsor/Collaborator : AstraZeneca

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Datopotamab Deruxtecan Gets Breakthrough Therapy Designation for EGFR-Mutated NSCLC

    Details : Dato-DXd (datopotamab deruxtecan) is a DNA topoisomerase I inhibitor candidate, which is being developed in patients with EGFR-mutated non-small cell lung cancer.

    Product Name : Dato-DXd

    Product Type : Antibody-drug Conjugate

    Upfront Cash : Inapplicable

    December 09, 2024

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Datopotamab Deruxtecan Shows Activity in EGFR-Mutated NSCLC in TROPION-Lung Studies

    Details:

    Dato-DXd (datopotamab deruxtecan) is a DNA topoisomerase I inhibitor candidate, which is being developed in patients with EGFR-mutated non-small cell lung cancer.


    Lead Product(s): Datopotamab Deruxtecan

    Therapeutic Area: Oncology Brand Name: Dato-DXd

    Study Phase: Phase IIIProduct Type: Antibody-drug Conjugate

    Sponsor: AstraZeneca

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable December 05, 2024

    blank

    09

    Daiichi Sankyo

    Japan
    arrow
    AACR Annual meeting
    Not Confirmed

    Daiichi Sankyo

    Japan
    arrow
    AACR Annual meeting
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Datopotamab Deruxtecan

    Therapeutic Area : Oncology

    Highest Development Status : Phase III

    Partner/Sponsor/Collaborator : AstraZeneca

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Datopotamab Deruxtecan Shows Activity in EGFR-Mutated NSCLC in TROPION-Lung Studies

    Details : Dato-DXd (datopotamab deruxtecan) is a DNA topoisomerase I inhibitor candidate, which is being developed in patients with EGFR-mutated non-small cell lung cancer.

    Product Name : Dato-DXd

    Product Type : Antibody-drug Conjugate

    Upfront Cash : Inapplicable

    December 05, 2024

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    ENHERTU® Granted PR for HER2 Low or Ultralow Metastatic Breast Cancer Patients

    Details:

    Enhertu (trastuzumab deruxtecan) is a HER2-directed ADC which is being evaluated for the treatment of previously treated patients with HR positive, HER2 low metastatic breast cancer.


    Lead Product(s): Trastuzumab Deruxtecan

    Therapeutic Area: Oncology Brand Name: Enhertu

    Study Phase: Phase IIIProduct Type: Antibody-drug Conjugate

    Sponsor: AstraZeneca

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable September 30, 2024

    blank

    10

    Daiichi Sankyo

    Japan
    arrow
    AACR Annual meeting
    Not Confirmed

    Daiichi Sankyo

    Japan
    arrow
    AACR Annual meeting
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Trastuzumab Deruxtecan

    Therapeutic Area : Oncology

    Highest Development Status : Phase III

    Partner/Sponsor/Collaborator : AstraZeneca

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    ENHERTU® Granted PR for HER2 Low or Ultralow Metastatic Breast Cancer Patients

    Details : Enhertu (trastuzumab deruxtecan) is a HER2-directed ADC which is being evaluated for the treatment of previously treated patients with HR positive, HER2 low metastatic breast cancer.

    Product Name : Enhertu

    Product Type : Antibody-drug Conjugate

    Upfront Cash : Inapplicable

    September 30, 2024

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    Only 10 entries up to this point, click to access all click full view read-more
    click full view
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    Inspections and registrations

    Upload your audits for free, ask us

    ABOUT THIS PAGE

    Contact Daiichi Sankyo Co Ltd and get a quotation

    Daiichi Sankyo Co Ltd is a supplier offers 77 products (APIs, Excipients or Intermediates).

    Find a price of Ofloxacin bulk with CEP offered by Daiichi Sankyo Co Ltd

    Find a price of Olmesartan Medoxomil bulk with CEP offered by Daiichi Sankyo Co Ltd

    Find a price of Pravastatin bulk with CEP offered by Daiichi Sankyo Co Ltd

    Find a price of Codeine bulk with JDMF offered by Daiichi Sankyo Co Ltd

    Find a price of Codeine Phosphate bulk with JDMF offered by Daiichi Sankyo Co Ltd

    Find a price of Deruxtecan bulk with DMF offered by Daiichi Sankyo Co Ltd

    Find a price of Etilevodopa bulk offered by Daiichi Sankyo Co Ltd

    Find a price of Human Ghrelin bulk with DMF offered by Daiichi Sankyo Co Ltd

    Find a price of Hydromorphone Hydrochloride bulk with JDMF offered by Daiichi Sankyo Co Ltd

    Find a price of Oxycodone Hydrochloride bulk with JDMF offered by Daiichi Sankyo Co Ltd

    Find a price of MUCOPOLYSACCHARIDE POLYSULFATE DRUG SUBSTANCE bulk with DMF offered by Daiichi Sankyo Co Ltd

    Find a price of 2-Naphthalenepropanoic Acid bulk offered by Daiichi Sankyo Co Ltd

    Find a price of Benfluorexum bulk offered by Daiichi Sankyo Co Ltd

    Find a price of Carperitide bulk offered by Daiichi Sankyo Co Ltd

    Find a price of Cefmetazole bulk offered by Daiichi Sankyo Co Ltd

    Find a price of Cefmetazole Sodium bulk offered by Daiichi Sankyo Co Ltd

    Find a price of Cefpodoxime Proxetil bulk offered by Daiichi Sankyo Co Ltd

    Find a price of Cetraxate bulk offered by Daiichi Sankyo Co Ltd

    Find a price of Cs 023 bulk offered by Daiichi Sankyo Co Ltd

    Find a price of Edoxaban Tosylate bulk offered by Daiichi Sankyo Co Ltd

    Find a price of Enkephalin, Methionine bulk offered by Daiichi Sankyo Co Ltd

    Find a price of Faropenem Medoxomil bulk offered by Daiichi Sankyo Co Ltd

    Find a price of Hydrochlorothiazide bulk offered by Daiichi Sankyo Co Ltd

    Find a price of L-VALINE bulk offered by Daiichi Sankyo Co Ltd

    Find a price of Levofloxacin bulk offered by Daiichi Sankyo Co Ltd

    Find a price of Levofloxacin Hydrochloride bulk offered by Daiichi Sankyo Co Ltd

    Find a price of MALOTILATE bulk offered by Daiichi Sankyo Co Ltd

    Find a price of Managlinat Dialanetil bulk offered by Daiichi Sankyo Co Ltd

    Find a price of Mepirizole bulk offered by Daiichi Sankyo Co Ltd

    Find a price of Nimustine bulk offered by Daiichi Sankyo Co Ltd

    Find a price of Ofloxacin bulk offered by Daiichi Sankyo Co Ltd

    Find a price of Olmesartan Medoxomil bulk offered by Daiichi Sankyo Co Ltd

    Find a price of Pantethine bulk offered by Daiichi Sankyo Co Ltd

    Find a price of Phenylalanine bulk offered by Daiichi Sankyo Co Ltd

    Find a price of Pravastatin bulk offered by Daiichi Sankyo Co Ltd

    Find a price of Temocapril Hydrochloride bulk offered by Daiichi Sankyo Co Ltd

    Find a price of Tranexamic Acid bulk offered by Daiichi Sankyo Co Ltd

    Find a price of Troglitazone bulk offered by Daiichi Sankyo Co Ltd

    Find a price of Tryptophan bulk offered by Daiichi Sankyo Co Ltd

    Find a price of BULK CS-045 ORAL HYPOGLYCEMIC bulk offered by Daiichi Sankyo Co Ltd

    Find a price of MANUFACTURING SITE, FACILITIES, PERSONNEL, AND GENERAL OPERATING PROCEDURES IN EDOGAWA-KU, TOKYO, JAPAN. bulk offered by Daiichi Sankyo Co Ltd

    Find a price of MIX-RR bulk offered by Daiichi Sankyo Co Ltd

    Find a price of DS-1594B DRUG SUBSTANCE bulk offered by Daiichi Sankyo Co Ltd

    Find a price of SUN13837 DRUG SUBSTANCE bulk offered by Daiichi Sankyo Co Ltd

    Find a price of CS-758 DRUG PRODUCT bulk offered by Daiichi Sankyo Co Ltd

    Find a price of DW-908E DRUG SUBSTANCE bulk offered by Daiichi Sankyo Co Ltd

    Find a price of DX-8951F DRUG SUBSTANCE bulk offered by Daiichi Sankyo Co Ltd

    Find a price of SUN N4057 DRUG SUBSTANCE bulk offered by Daiichi Sankyo Co Ltd

    Find a price of CS-003 DRUG SUBSTANCE bulk offered by Daiichi Sankyo Co Ltd

    Find a price of PARENTERAL FORMULATION FACILITY IN OSAKA, JAPAN. bulk offered by Daiichi Sankyo Co Ltd

    Find a price of FACILITIES AND OPERATING PROCEDURES IN HIRATSUKA-SHI, JAPAN bulk offered by Daiichi Sankyo Co Ltd

    Find a price of DL 8280 MEFOXACIN ACTIVE & PLACEBO TABS bulk offered by Daiichi Sankyo Co Ltd

    Find a price of DS-1594B DRUG PRODUCT bulk offered by Daiichi Sankyo Co Ltd

    Find a price of SUN13834 DRUG SUBSTANCE bulk offered by Daiichi Sankyo Co Ltd

    Find a price of DATICHI PHARMACEUTICAL CO LTD DU-6859A bulk offered by Daiichi Sankyo Co Ltd

    Find a price of DX-619 DRUG SUBSTANCE bulk offered by Daiichi Sankyo Co Ltd

    Find a price of CS-505 DRUG SUBSTANCE bulk offered by Daiichi Sankyo Co Ltd

    Find a price of CS-011 DRUG PRODUCT bulk offered by Daiichi Sankyo Co Ltd

    Find a price of CS-003 DRUG PRODUCT bulk offered by Daiichi Sankyo Co Ltd

    Find a price of CS-834 DRUG PRODUCT bulk offered by Daiichi Sankyo Co Ltd

    Find a price of DS-4152 DRUG SUBSTANCE bulk offered by Daiichi Sankyo Co Ltd

    Find a price of DT-5621 DRUG SUBSTANCE bulk offered by Daiichi Sankyo Co Ltd

    Find a price of PANTOSIN 200 MG TABLETS bulk offered by Daiichi Sankyo Co Ltd

    Find a price of PRODUCTION TECHNOLOGY RESEARCH LABS., EDOGAWA-KU, TOKYO, JAPAN bulk offered by Daiichi Sankyo Co Ltd

    Find a price of MANUFACTURING SITE, FACILITIES, PERSONNEL, AND GENERAL OPERATING PROCEDURES IN SHIZUOKA JAPAN. bulk offered by Daiichi Sankyo Co Ltd

    Find a price of POLYSULFATED GLYCOSAMINOGLYCAN (PSGAG) bulk offered by Daiichi Sankyo Co Ltd

    Find a price of CS-758 DRUG SUBSTANCE bulk offered by Daiichi Sankyo Co Ltd

    Find a price of DZ-697B DRUG SUBSTANCE bulk offered by Daiichi Sankyo Co Ltd

    Find a price of CS-505 DRUG PRODUCT bulk offered by Daiichi Sankyo Co Ltd

    Find a price of DE-310 DRUG SUBSTANCE bulk offered by Daiichi Sankyo Co Ltd

    Find a price of DK-507K DRUG SUBSTANCE bulk offered by Daiichi Sankyo Co Ltd

    Find a price of CS-780 DRUG PRODUCT bulk offered by Daiichi Sankyo Co Ltd

    Find a price of SUN N 8075 DRUG SUBSTANCE bulk offered by Daiichi Sankyo Co Ltd

    Find a price of CS-834 DRUG SUBSTANCE bulk offered by Daiichi Sankyo Co Ltd

    Find a price of Glycosaminoglycan bulk offered by Daiichi Sankyo Co Ltd

    Find a price of Loxoprofen Sodium bulk offered by Daiichi Sankyo Co Ltd

    Find a price of Mirogabalin Besylate bulk offered by Daiichi Sankyo Co Ltd

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search